Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CFO Sandip Kapadia sold 354 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.83, for a total value of $20,825.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded down 3.39% on Friday, reaching $65.49. The company’s stock had a trading volume of 1,049,123 shares. The stock’s market capitalization is $1.64 billion. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $142.10. The stock has a 50-day moving average of $86.63 and a 200 day moving average of $108.69.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period in the prior year, the company earned ($3.14) EPS. On average, analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.99) EPS for the current year.

WARNING: This piece was posted by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at http://www.mareainformativa.com/intercept-pharmaceuticals-inc-icpt-cfo-sandip-kapadia-sells-354-shares-of-stock/117630/.

A number of brokerages have issued reports on ICPT. JMP Securities lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 4th. Wedbush reissued an “outperform” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. Royal Bank Of Canada raised their price target on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 26th. Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Finally, Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $153.76.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WFG Advisors LP boosted its position in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE bought a new position in Intercept Pharmaceuticals in the 1st quarter valued at $130,000. IFP Advisors Inc boosted its position in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Intercept Pharmaceuticals in the 1st quarter valued at $170,000. Institutional investors and hedge funds own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.